Synklino ApS, a Copenhagen, Denmark-based biotech company developing first-in-class breakthrough treatment to eliminate cytomegalovirus (CMV) infections in the transplant setting, closed a seed financing round of undisclosed amount.
The round was led by Eir Ventures and Vaekstfonden.
A spinout from the University of Copenhagen and the Technical University of Denmark led by Thomas Kledal, CEO, Synklino was established to develop therapies against viral infections. The company is incubated at the BioInnovation Institute in its Creation House program.
CMV is a virus that infects most people in adulthood and is the main agent involved in infectious complications following transplantation with major risk for morbidity, transplantation complications and increased hospital readmissions. Synklino’s drug candidate SYN002 has the potential to eliminate CMV from infected patients by targeting both lytic and latent infection.